Development of a Functional Assessment Scale for Ambulatory Boys with Duchenne Muscular Dystrophy

Physiotherapy Research International

Volumn 17, Issue 2, 2012, Pages 101-109

  Scott, Elaine ^a   Eagle, Michelle ^b   Mayhew, Anna ^c   Freeman, Jenny ^c   Main, Marion ^d   Sheehan, Jennie ^e   Manzur, Adnan ^f   Muntoni, Francesco ^f  

^a Muscular Dystrophy Campaign   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ambulant; Assessment; Duchenne muscular dystrophy

Indexed keywords

ARTICLE; CHILD; CLINICAL TRIAL; DISABILITY; DUCHENNE MUSCULAR DYSTROPHY; EDUCATION; HUMAN; INFORMATION PROCESSING; MALE; MULTICENTER STUDY; OBSERVER VARIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PHYSIOTHERAPIST; REPRODUCIBILITY; UNITED KINGDOM; VALIDATION STUDY; WALKING;

CHILD; DISABILITY EVALUATION; FOCUS GROUPS; GREAT BRITAIN; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; OBSERVER VARIATION; PHYSICAL THERAPISTS; REPRODUCIBILITY OF RESULTS; WALKING;

EID: 84862004315     PISSN: 13582267     EISSN: 15206483     Source Type: Journal    
DOI: 10.1002/pri.520     Document Type: Article

References (26)

1. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991.
2. Bain BA, Dollaghan CA. Clinical forum: treatment efficacy. The notion of clinically significant change. Language, Speech, and Hearing Services in Schools 1991; 22(10): 264-270.
3. Bérard C, Payan C, Fermanian J, Girardot F, Groupe d'Etude MFM. A motor function measurement scale for neuromuscular diseases-description and validation study (in French). Revue Neurologique (Paris) 2006; 162(4): 485-493.
4. Bérard C, Payan C, Hodgkinson I, Fermanian J, MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscular Disorders 2005; 15(7): 463-470.
5. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle & Nerve 1981; 4(3): 186-197.
6. Cirak S, Muntoni F, Guglieri M, Bushby K, Leow S, Shrewsbury S. Current progress with the systemic administration trial of AVI-4658, a novel phosphorodiamidate morpholino oligomer (PMO) skipping exon 51 in Duchenne muscular dystrophy (DMD). World Muscle Society Meeting, Geneva, 9-12 September 2009. Neuromuscular Disorders 2009; 19(8-9): 511-674.
7. Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, Iannaccone ST. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. Journal of Clinical Neuromuscular Disease 2010; 11(3): 97-109.
8. Emery EH, Muntoni F. In: Emery AEH, Muntoni F (eds), Duchenne Muscular Dystrophy (3rd edition). Oxford: Oxford University Press, 2003.
9. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educational and Psychological Measurement 1973; 33: 613-619.
10. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F. Local restoration of dystrophin expression in Duchenne muscular dystrophy: a single blind, placebo-controlled dose escalation study using morpholino antisense oligomer AVI-4658. Lancet Neurology 2009; 8(10): 918-928.
11. Kohler M, Clarenbach CF, Böni L, Brack T, Russi EW, Bloch KE. Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. American Journal of Respiratory and Critical Care Medicine 2005; 172(8): 1032-1036.
12. Manzur AY, Kuntzer T, Pike M, Swan AV. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2008a, Issue 1. Art. No. CD003725. DOI: 10.1002/14651858.CD003725.pub3.
13. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Archives of Disease in Childhood 2008b; 93(11): 986-990. Invited review.
14. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle & Nerve 2007; 35(1): 36-42.
15. Mazzone ES, Messina S, Vasco G, Main M, Eagle M, D'Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Magri F, Corlatti A, Zucchini E, Brancalion B, Rossi F, Ferretti M, Motta MG, Cecio MR, Berardinelli A, Alfieri P, Mongini T, Pini A, Astrea G, Battini R, Comi G, Pegoraro E, Morandi L, Pane M, Angelini C, Bruno C, Villanova M, Vita G, Donati MA, Bertini E, Mercuri E. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders 2009; 19(7): 458-461.
16. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve 2010; 41(4): 500-510.
17. McDonald CM. Physical activity, health impairments, and disability in neuromuscular disease. American Journal of Physical Medicine & Rehabilitation 2002; 81(11 Suppl): S108-S120.
18. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K. TREAT-NMD Neuromuscular Network. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th-13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June-1st July, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscular Disorders 2008; 18: 894-903.
19. Portney L, Watkins M. Validity of Measurements. In: Foundations of Clinical Research. Applications to Practice. New Jersey: Prentice Hall Health, 2000: 79-110.
20. Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. Developmental Medicine and Child Neurology 2006; 48(6): 540-544.
21. Scott E, Mayhew A, Muntoni F, Manzur AY. NorthStar and SMARTnet: development of paediatric neuromuscular disease networks in the UK. Developmental Medicine and Child Neurology 2007; 49(Supplement No. 108): 29.
22. Scott OM, Hyde SA, Goddard C, Dubowitz, V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle & Nerve 1982; 5(4): 291-301.
23. Steffensen B, Hyde S, Lyager S, Mattsson E. Validity of the EK Scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiotherapy Research International 2001; 6(3): 119-134.
24. Steffensen BF, Lyager S, Werge B, Rahbek J, Mattson E. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Developmental Medicine and Child Neurology 2002; 44(9): 623-632.
25. Streiner DL, Norman GR. 2003. Health Measurement Scales: A Practical Guide to Their Development and Use (3rd edition). Oxford: Oxford Medical Publications.
26. Vignos PJ, Jr, Spencer GE, Jr, Archibald KC. Management of progressive muscular dystrophy in childhood. JAMA 1963; 184: 89-96.